34 articles for A Vulpetti
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Novartis Pharma
6
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.
Novartis Institutes For Biomedical Research
36
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Nerviano Medical Sciences
50
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Nerviano Medical Sciences
13
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches.
Novartis
11
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase.
Novartis Institutes for Biomedical Research
13
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field.
Novartis Institutes for Biomedical Research
14
Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
Novartis Institutes For Biomedical Research
17
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Novartis Institutes For Biomedical Research
16
Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects.
Lavis
31
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
TBA
18
Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.
Novartis Pharma
13
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model.
TBA
27
3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
Novartis
4
Design, Synthesis, and Experimental Validation of Peptide Ligands Targeting Mycobacterium tuberculosis s Factors.
Indian Institute of Science
3
Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.
University of Kentucky
7
Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors.
Lanzhou University
8
Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein.
Beactica
6
Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function.
Astex Pharmaceuticals
4
Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Taisho Pharmaceutical
11
Structural analysis of inhibitor binding to human carbonic anhydrase II.
University of Pennsylvania
10
Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
University of Pennsylvania
18
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Japan Energy
10
Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
Stockholm University